IN2014MN02089A - - Google Patents
Info
- Publication number
- IN2014MN02089A IN2014MN02089A IN2089MUN2014A IN2014MN02089A IN 2014MN02089 A IN2014MN02089 A IN 2014MN02089A IN 2089MUN2014 A IN2089MUN2014 A IN 2089MUN2014A IN 2014MN02089 A IN2014MN02089 A IN 2014MN02089A
- Authority
- IN
- India
- Prior art keywords
- subject
- blood transfusion
- blood
- efficacy
- administering
- Prior art date
Links
- 239000008280 blood Substances 0.000 abstract 2
- 210000004369 blood Anatomy 0.000 abstract 2
- 102000004506 Blood Proteins Human genes 0.000 abstract 1
- 108010017384 Blood Proteins Proteins 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/18—Erythrocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
- A61K38/385—Serum albumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/41—Porphyrin- or corrin-ring-containing peptides
- A61K38/42—Haemoglobins; Myoglobins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/765—Serum albumin, e.g. HSA
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/795—Porphyrin- or corrin-ring-containing peptides
- C07K14/805—Haemoglobins; Myoglobins
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261613105P | 2012-03-20 | 2012-03-20 | |
| PCT/US2013/030355 WO2013142135A1 (en) | 2012-03-20 | 2013-03-12 | Method of enhancing efficacy of blood transfusions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014MN02089A true IN2014MN02089A (cs) | 2015-09-11 |
Family
ID=49223191
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN2089MUN2014 IN2014MN02089A (cs) | 2012-03-20 | 2013-03-12 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US8859499B2 (cs) |
| EP (1) | EP2827887A4 (cs) |
| JP (1) | JP2015515462A (cs) |
| BR (1) | BR112014023200A2 (cs) |
| CL (1) | CL2014002464A1 (cs) |
| HK (1) | HK1204267A1 (cs) |
| IN (1) | IN2014MN02089A (cs) |
| MX (1) | MX2014011186A (cs) |
| WO (1) | WO2013142135A1 (cs) |
| ZA (1) | ZA201407616B (cs) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20160208011A1 (en) | 2010-01-28 | 2016-07-21 | The Board Of Trustees Of The Leland Stanford Junior University | Ccr3 modulation in the treatment of aging-associated impairments, and compositions for practicing the same |
| US10626399B2 (en) | 2010-01-28 | 2020-04-21 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of treating cognitive symptoms of an aging-associated impairment by modulating C-C chemokine receptor type 3 (CCR3) |
| US10487148B2 (en) | 2010-01-28 | 2019-11-26 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for treating aging-associated impairments |
| US9161968B2 (en) | 2011-04-08 | 2015-10-20 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of neuroprotection involving macrophage colony stimulating factor receptor agonists |
| IN2014MN02089A (cs) | 2012-03-20 | 2015-09-11 | Einstein Coll Med | |
| US10905779B2 (en) | 2013-12-09 | 2021-02-02 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for screening human blood products comprising plasma using immunocompromised rodent models |
| EA035336B1 (ru) | 2013-12-09 | 2020-05-29 | Зе Боард Оф Трастиз Оф Зе Леланд Стэнфорд Джуниор Юниверсити | Способ лечения связанного со старением когнитивного расстройства или заболевания |
| EP3218011A4 (en) * | 2014-11-14 | 2018-06-27 | Aima Biotech | Conjugated proteins |
| US20170258937A1 (en) | 2014-11-25 | 2017-09-14 | Nanobiotix | Pharmaceutical composition, preparation and uses thereof |
| EP3096160B1 (en) * | 2015-05-20 | 2020-02-26 | Veoneer Sweden AB | An fmcw vehicle radar system |
| TW202417036A (zh) | 2015-05-28 | 2024-05-01 | 法商奈諾生技公司 | 作為治療疫苗之奈米顆粒 |
| DK3307296T3 (da) | 2015-06-15 | 2021-12-13 | Univ Leland Stanford Junior | Timp2 til anvendelse til behandling af aldringsassocierede tilstande |
| WO2017083281A1 (en) * | 2015-11-09 | 2017-05-18 | Albert Einstein College Of Medicine, Inc. | Method of ameliorating side effects of sickle cell disease treatments |
| WO2017103914A1 (en) | 2015-12-17 | 2017-06-22 | Regentis Biomaterials Ltd. | Ready for use organic solvent free compositions comprising protein-polymer conjugates and uses thereof |
| ES3037703T3 (en) | 2016-04-28 | 2025-10-06 | Alkahest Inc | Blood plasma and plasma fractions as therapy for tumor growth and progression |
| US10525107B2 (en) | 2016-08-18 | 2020-01-07 | Alkahest, Inc. | Blood plasma fractions as a treatment for aging-associated cognitive disorders |
| AU2018257921B2 (en) | 2017-04-26 | 2024-06-06 | Alkahest, Inc. | Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products |
| US11040068B2 (en) | 2017-04-26 | 2021-06-22 | Alkahest, Inc. | Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products |
| WO2019018403A1 (en) | 2017-07-18 | 2019-01-24 | Virtech Bio, Llc | BLOOD SUBSTITUTES COMPRISING HEMOGLOBIN AND METHODS OF MAKING |
| UA128648C2 (uk) | 2018-10-26 | 2024-09-18 | Алкахест, Інк. | Застосування плазми крові та фракцій плазми для пом'якшення болю, поліпшення загоювання ран та післяопераційного відновлення |
| JP7773169B2 (ja) * | 2021-02-24 | 2025-11-19 | 学校法人 中央大学 | ポリオキサゾリン結合アルブミン、人工血漿増量剤及び出血ショックの蘇生液 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4267269A (en) * | 1980-02-05 | 1981-05-12 | Baxter Travenol Laboratories, Inc. | Red cell storage solution |
| JPS56139419A (en) * | 1980-03-31 | 1981-10-30 | Kuraray Co Ltd | Erythrocytic preservative and erythrocytic pharmaceutical for preservation |
| AU752037B2 (en) * | 1997-09-26 | 2002-09-05 | Uab Research Foundation | Reduced antigenic cells and uses therefor |
| EP1115414B1 (en) * | 1998-09-25 | 2003-12-17 | Oklahoma Medical Research Foundation | Inhibition of erythrocyte sickling by n-l-alpha-aspartyl-l-phenylalanine 1-methyl ester |
| US6251927B1 (en) * | 1999-04-20 | 2001-06-26 | Medinox, Inc. | Methods for treatment of sickle cell anemia |
| US6875423B1 (en) * | 1999-09-21 | 2005-04-05 | Marcos Intaglietta | Methods for increasing peripheral blood circulation |
| WO2001034648A1 (en) * | 1999-11-12 | 2001-05-17 | Baxter International, Inc. | Reduced side-effect hemoglobin compositions |
| US6811778B2 (en) | 2001-09-10 | 2004-11-02 | Biopure Corporation | Method for improving oxygen transport by stored red blood cells |
| US20080194481A1 (en) * | 2001-12-21 | 2008-08-14 | Human Genome Sciences, Inc. | Albumin Fusion Proteins |
| US7144989B2 (en) * | 2002-03-25 | 2006-12-05 | Albert Einstein College Of Medicine Of Yeshiva University | Pegylated non-hypertensive hemoglobins, methods of preparing same, and uses thereof |
| US7521174B2 (en) * | 2003-12-05 | 2009-04-21 | Albert Einstein College Of Medicine Of Yeshiva University | Universal red blood cells, methods of preparing same, and uses thereof |
| EP1819330A1 (en) * | 2004-12-01 | 2007-08-22 | Devgen N.V. | 5-carboxamido substitued thiazole derivatives that interact with ion channels, in particular with ion channels from the kv family |
| WO2006135740A1 (en) | 2005-06-10 | 2006-12-21 | Albert Einstein College Of Medicine Of Yeshiva University | Pegylated hemoglobin and albumin and uses thereof |
| US8071546B2 (en) * | 2005-06-10 | 2011-12-06 | La Jolla Bioengineering Institute | Uses of pegylated albumin |
| EP2391341A4 (en) * | 2009-01-30 | 2012-05-09 | Cuthbert O Simpkins | REVIVAL LIQUID |
| US8815297B2 (en) * | 2009-03-31 | 2014-08-26 | Duke University | Modulation of beta 2 adrenergic receptors by inhibitors of EGLN3 or pVHL |
| DK3266463T3 (da) * | 2009-06-09 | 2024-01-08 | Prolong Pharmaceuticals Llc | Hæmoglobinsammensætninger |
| US20110189166A1 (en) * | 2010-01-29 | 2011-08-04 | John Boucher | Methods of treating hemorheologic abnormalities in mammals |
| US20130231287A1 (en) * | 2010-02-25 | 2013-09-05 | Parimala Nacharaju | Pegylated albumin polymers and uses thereof |
| IN2014MN02089A (cs) | 2012-03-20 | 2015-09-11 | Einstein Coll Med | |
| EP3218011A4 (en) | 2014-11-14 | 2018-06-27 | Aima Biotech | Conjugated proteins |
-
2013
- 2013-03-12 IN IN2089MUN2014 patent/IN2014MN02089A/en unknown
- 2013-03-12 BR BR112014023200A patent/BR112014023200A2/pt not_active IP Right Cessation
- 2013-03-12 MX MX2014011186A patent/MX2014011186A/es unknown
- 2013-03-12 JP JP2015501731A patent/JP2015515462A/ja active Pending
- 2013-03-12 US US13/794,978 patent/US8859499B2/en active Active
- 2013-03-12 WO PCT/US2013/030355 patent/WO2013142135A1/en not_active Ceased
- 2013-03-12 HK HK15104771.0A patent/HK1204267A1/xx unknown
- 2013-03-12 EP EP13764824.2A patent/EP2827887A4/en not_active Withdrawn
-
2014
- 2014-08-07 US US14/454,059 patent/US9498537B2/en active Active
- 2014-09-17 CL CL2014002464A patent/CL2014002464A1/es unknown
- 2014-10-20 ZA ZA2014/07616A patent/ZA201407616B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2827887A4 (en) | 2016-04-20 |
| US20150017146A1 (en) | 2015-01-15 |
| BR112014023200A2 (pt) | 2018-09-18 |
| CL2014002464A1 (es) | 2015-08-28 |
| US20130261061A1 (en) | 2013-10-03 |
| MX2014011186A (es) | 2015-03-06 |
| WO2013142135A1 (en) | 2013-09-26 |
| US8859499B2 (en) | 2014-10-14 |
| US9498537B2 (en) | 2016-11-22 |
| JP2015515462A (ja) | 2015-05-28 |
| HK1204267A1 (en) | 2015-11-13 |
| ZA201407616B (en) | 2016-08-31 |
| EP2827887A1 (en) | 2015-01-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014MN02089A (cs) | ||
| EP2702994A3 (en) | Methods of administering pirfenidone therapy | |
| MX353482B (es) | Metodos para el tratamiento del cancer y enfermedades inflamatorias utilizando cereblon como predictor. | |
| PH12014501702A1 (en) | Imidazopyrrolidinone compounds | |
| EA201491773A1 (ru) | Лечение рассеянного склероза комбинацией лаквинимода и диметилфумарата | |
| ZA201408119B (en) | Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof | |
| PH12015502042A1 (en) | Use of linagliptin in cardio-and renoprotective antidiabetic therapy | |
| AP2014007533A0 (en) | Substituted benzylindazoles for use as BUB1 kinaseinhibitors in the treatment of hyperproliferative diseases | |
| EA201991014A1 (ru) | Лечение диабета | |
| HK1204578A1 (en) | Medicament for the treatment of acute myeloid leukemia (aml) | |
| MY188139A (en) | Sodium channel modulators for the treatment of pain | |
| EA201491500A1 (ru) | Способы лечения фиброза | |
| GB201207543D0 (en) | Treatment of transfusion blood | |
| PH12014502551A1 (en) | Oligonucleotide chelate complex-polypeptide compositions and methods | |
| SG191060A1 (en) | Robo1-fc fusion protein for use in the treatment of hepatocarcinoma | |
| EA201500370A1 (ru) | ФАРМАЦЕВТИЧЕСКИЕ КОМБИНАЦИИ, СОДЕРЖАЩИЕ ДВОЙНЫЕ АНГИОПОЭТИН-2/Dll4 СВЯЗЫВАЮЩИЕ АГЕНТЫ И АНТИ-VEGF-R АГЕНТЫ | |
| GB201022049D0 (en) | Methods | |
| IL239078A0 (en) | Protein for use in the treatment of eye diseases | |
| MX362111B (es) | Un metodo para mejorar la funcion hepatica. | |
| WO2014005153A3 (en) | Methods for treating mds1-evi1 mediated cancer | |
| HK40043513B (en) | Interval therapy for the treatment of eye diseases | |
| EA201492161A1 (ru) | N-метил-4-бензилкарбамидопиридиний хлорид и способ его получения | |
| GB201206628D0 (en) | Subcutaneous administration of PEGylated blood clotting factors | |
| HK1220133A1 (zh) | 改善微血管完整性的方法 | |
| UA97741C2 (ru) | Способ восстановления кожных покровов при глубоких распространенных ожогах микроаутодермотрансплантатами |